AOMS1
MCID: ABD017
MIFTS: 46

Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2 (AOMS1)

Categories: Blood diseases, Genetic diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

MalaCards integrated aliases for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2:

Name: Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2 57
Abdominal Obesity-Metabolic Syndrome 57 12 36 13 15
Abdominal Obesity Metabolic Syndrome 20 70
Metabolic Syndrome X 20 70
Aoms1 20
Aoms2 57

Characteristics:

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
autosomal dominant


HPO:

31
abdominal obesity-metabolic syndrome quantitative trait locus 2:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:0060611
OMIM® 57 605572
OMIM Phenotypic Series 57 PS605552
KEGG 36 H02384
MedGen 41 C1854170
UMLS 70 C0524620 C2930930

Summaries for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

KEGG : 36 Abdominal obesity-metabolic syndrome (AOMS) is also known as syndrome X or insulin resistance syndrome. Insulin resistance is a key abnormality associated with an atherogenic, prothrombotic, and inflammatory profile. The most prevalent form of this constellation of metabolic abnormalities is found in patients with abdominal obesity, especially with an excess of intra-abdominal or visceral adipose tissue. Recently, a few causative gene mutations have been reported.

MalaCards based summary : Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2, also known as abdominal obesity-metabolic syndrome, is related to abdominal obesity-metabolic syndrome 1 and polycystic ovary syndrome, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2 is AOMS1 (Abdominal Obesity-Metabolic Syndrome QTL1), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). The drugs Galantamine and Fenofibrate have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and endothelial, and related phenotypes are hypertension and abdominal obesity

Disease Ontology : 12 A syndrome that is characterized by abdominal obesity, blood lipid disorders, inflammation, insulin resistance or full-blown diabetes, and increased risk of developing cardiovascular disease.

More information from OMIM: 605572 PS605552

Related Diseases for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Diseases related to Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 175)
# Related Disease Score Top Affiliating Genes
1 abdominal obesity-metabolic syndrome 1 30.8 SLC2A4 SERPINE1 PPARG PPARD LEP INS
2 polycystic ovary syndrome 30.2 PPARG LEP INS ADIPOQ
3 hyperinsulinism 30.2 SLC2A4 SERPINE1 PPARG LEP INS ADIPOQ
4 coronary heart disease 1 30.1 SERPINE1 INS CRP ADIPOQ
5 hyperuricemia 30.1 PPARG LEP INS CRP
6 retinal artery occlusion 29.8 SERPINE1 IL6 CRP
7 type 1 diabetes mellitus 29.8 LEP INS IL6 CRP ADIPOQ
8 angina pectoris 29.7 INS IL6 CRP ADIPOQ
9 hyperglycemia 29.7 SERPINE1 PPARG LEP INS IL6 ADIPOQ
10 glucose intolerance 29.7 SLC2A4 PPARG LEP INS IL6 CRP
11 proteasome-associated autoinflammatory syndrome 1 29.5 PPARG INS IL6 CRP ADIPOQ
12 familial hyperlipidemia 29.5 SERPINE1 PPARG LEP INS CRP ADIPOQ
13 atherosclerosis susceptibility 29.3 SERPINE1 PPARG LEP INS IL6 CRP
14 vascular disease 29.3 SERPINE1 PPARG LEP INS IL6 CRP
15 hypertension, essential 29.3 SLC2A4 SERPINE1 PPARG LEP INS IL6
16 lipid metabolism disorder 29.3 SERPINE1 PPARG PPARD LEP INS IL6
17 non-alcoholic fatty liver disease 28.8 SLC2A4 SERPINE1 PPARG LEP INS IL6
18 cardiovascular system disease 28.6 SERPINE1 PPARG PPARD LEP INS IL6
19 type 2 diabetes mellitus 28.5 SLC2A4 SERPINE1 PPARG PPARD LEP INS
20 body mass index quantitative trait locus 11 28.3 SLC2A4 SERPINE1 PPARG PPARD LEP INS
21 diabetes mellitus 28.3 SLC2A4 SERPINE1 PPARG PPARD LEP INS
22 abdominal obesity-metabolic syndrome 3 11.9
23 abdominal obesity-metabolic syndrome 4 11.0
24 idiopathic recurrent pericarditis 10.4 LEP ADIPOQ
25 hypothalamic obesity 10.4 LEP INS
26 malignant otitis externa 10.3 INS CRP
27 uvulitis 10.3 INS CRP
28 nontuberculous mycobacterial lung disease 10.3 LEP ADIPOQ
29 pica disease 10.3 LEP INS
30 diencephalic astrocytoma 10.3 LEP INS
31 cavernous sinus thrombosis 10.3 INS CRP
32 idiopathic edema 10.3 PPARG INS ADIPOQ
33 silent myocardial infarction 10.3 INS CRP
34 neurogenic arthropathy 10.3 INS CRP
35 critical illness polyneuropathy 10.3 INS CRP
36 mediastinitis 10.3 INS CRP
37 pellagra 10.2 PPARG INS ADIPOQ
38 inflammatory and toxic neuropathy 10.2 INS CRP
39 lipodystrophy, congenital generalized, type 2 10.2 PPARG LEP INS
40 balanitis 10.2 INS CRP
41 hyperandrogenism 10.2 PPARG INS ADIPOQ
42 anovulation 10.2 LEP INS CRP
43 benign essential hypertension 10.2 INS CRP
44 cholelithiasis 10.2 LEP INS CRP
45 cold agglutinin disease 10.2 IL6 CRP
46 acute insulin response 10.2 INS CRP
47 prosthetic joint infection 10.2 IL6 CRP
48 complete generalized lipodystrophy 10.2 PPARG LEP INS ADIPOQ
49 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 10.2 PPARG LEP INS ADIPOQ
50 uremic pruritus 10.2 IL6 CRP

Graphical network of the top 20 diseases related to Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2:



Diseases related to Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Symptoms & Phenotypes for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Human phenotypes related to Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2:

31
# Description HPO Frequency HPO Source Accession
1 hypertension 31 HP:0000822
2 abdominal obesity 31 HP:0012743

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Cardiovascular Vascular:
hypertension

Laboratory Abnormalities:
elevated fasting glucose levels

Growth Weight:
abdominal obesity

Clinical features from OMIM®:

605572 (Updated 20-May-2021)

UMLS symptoms related to Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2:


angina pectoris; chest pain; edema

MGI Mouse Phenotypes related to Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 9.91 ADIPOQ AWAT1 IL6 INS LEP PPARD
2 immune system MP:0005387 9.9 ADIPOQ BPGM CRP IL6 INS LEP
3 liver/biliary system MP:0005370 9.65 ADIPOQ IL6 INS LEP MAN2A2 PPARD
4 renal/urinary system MP:0005367 9.23 ADIPOQ IL6 INS LEP MAN2A2 PPARG

Drugs & Therapeutics for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Drugs for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Galantamine Approved Phase 4 357-70-0 9651
2
Fenofibrate Approved Phase 4 49562-28-9 3339
3
Atorvastatin Approved Phase 4 134523-00-5 60823
4
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
5
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
6
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
7
Polyestradiol phosphate Approved Phase 4 28014-46-2
8
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
9
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
10
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
11
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
12
Eplerenone Approved Phase 4 107724-20-9 150310 443872
13
Ramipril Approved Phase 4 87333-19-5 5362129
14
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
15
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
16 Cholinesterase Inhibitors Phase 4
17 Cholinergic Agents Phase 4
18 Cholinergic Antagonists Phase 4
19 Nootropic Agents Phase 4
20 Neurotransmitter Agents Phase 4
21 Trace Elements Phase 4
22 Nutrients Phase 4
23 Vitamin B9 Phase 4
24 Folate Phase 4
25 Vitamin B Complex Phase 4
26 Micronutrients Phase 4
27 Vitamins Phase 4
28 Hypoglycemic Agents Phase 4
29 Plasminogen Inactivators Phase 4
30 Plasminogen Phase 4
31 Anti-Infective Agents Phase 4
32 Antimetabolites Phase 4
33 Hypolipidemic Agents Phase 4
34 Lipid Regulating Agents Phase 4
35 Platelet Aggregation Inhibitors Phase 4
36 Calcium, Dietary Phase 4
37 Rosuvastatin Calcium Phase 4 147098-20-2
38 Anticholesteremic Agents Phase 4
39 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
40 Vasodilator Agents Phase 4
41 Vitamin B3 Phase 4
42 Nicotinic Acids Phase 4
43 Purinergic P2Y Receptor Antagonists Phase 4
44 Contraceptive Agents Phase 4
45 Estradiol 3-benzoate Phase 4
46 Estradiol 17 beta-cypionate Phase 4
47 Contraceptives, Oral Phase 4
48 Contraceptives, Oral, Combined Phase 4
49 Anti-Bacterial Agents Phase 4
50 Norgestimate, ethinyl estradiol drug combination Phase 4

Interventional clinical trials:

(show top 50) (show all 100)
# Name Status NCT ID Phase Drugs
1 Effects of Cholinergic Stimulation on Visceral Fat, Oxidative Stress and Inflammatory Markers in Patients With Metabolic Syndrome: a Randomized Clinical Trial Completed NCT02283242 Phase 4 Galantamine;Placebo (for galantamine)
2 The Effects of Night-time Versus Morning Administration of Eplerenone on the Diurnal Variation of Plasminogen Activator Inhibitor-1 Completed NCT00515021 Phase 4 Eplerenone (Morning);Eplerenone (Night-time)
3 A 6-week, Randomised, Open-label, Parallel Group, Multi-centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Metabolic Syndrome Subjects With Raised LDL-C Completed NCT00395486 Phase 4 Rosuvastatin;Atorvastatin
4 Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia Completed NCT00304993 Phase 4 fenofibrate;niacin;rosiglitazone
5 PROCLAIM: Pilot Study Examining Effects of Clopidogrel Compared to Placebo on Markers of Inflammation in Subjects With Metabolic Syndrome Completed NCT00296803 Phase 4 clopidogrel
6 Oral Contraceptives in the Metabolic Syndrome Completed NCT00205504 Phase 4 Ortho Tri Cyclen
7 Effects of Aldosterone Antagonism on Insulin-mediated Microvascular Function in Subjects With the Metabolic Syndrome Terminated NCT01887119 Phase 4 Eplerenone
8 Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity Terminated NCT00608465 Phase 4 Eplerenone;Ramipril
9 Effect of a Meal Replacement on Weight Loss Obesity Patients With Metabolic Syndrome : A Randomized Controlled Trial Unknown status NCT02626741 Phase 3
10 Effect of Exercise on Prescription on Physical Activity, Physical Fitness, and Health in Patients With Lifestyle Diseases Unknown status NCT00399997 Phase 2, Phase 3
11 The Effects of Walnut Supplement on Cardio-Metabolic Risk Factors in Patients With Metabolic Syndrome Completed NCT00742742 Phase 2, Phase 3
12 The Effects of Flaxseed Supplement on Cardio-metabolic Risk Factors in Patients With Metabolic Syndrome Completed NCT00733772 Phase 2, Phase 3
13 A Randomized Prevention Trial Substituting Brown Rice for White Rice to Lower Markers for Diabetes Risk Completed NCT01022411 Phase 2, Phase 3
14 The Improvements of Dietary Supplement of Black Rice on Metabolic Syndrome and Its Correlation With Metabolism of Gut Microbiota Completed NCT02407522 Phase 2, Phase 3
15 A Randomized, Double Blind, 2X2 Factorial Design Study to Evaluate the Effects of Telmisartan vs Placebo, and of a Low-Glycemic Diet vs Control Diet, in Reducing Intra-Myocellular Lipids In Individuals With Abdominal Obesity Completed NCT00147264 Phase 3 Telmisartan (Micardis®) vs. Placebo
16 Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome Completed NCT00111956 Phase 2, Phase 3 Etanercept;Placebo
17 Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion Completed NCT02113241 Phase 2, Phase 3 Dapagliflozin;Placebo
18 Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study Completed NCT01849068 Phase 3 Ezetimibe;Placebo
19 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Efficacy of Topiramate for Weight Loss in Subjects With Metabolic Syndrome Suspended NCT00243984 Phase 3 topiramate
20 A Randomized, Double-Blind, Placebo Controlled, Multicenter, 12-week Phase 3 Study to Evaluate Efficacy and Safety of ALS-L1023 Tablet in Patients With Abdominal Obesity of Metabolic Syndrome Terminated NCT01872182 Phase 3 ALS-L1023;placebo
21 Double-blind, Placebo Controlled, Randomised, Cross-over Study to Determine the Effect of a Prebiotic Galactooligosaccharide on Microbiota and Metabolic Syndrome Risk Factors in Overweight Adults Completed NCT01004120 Phase 1, Phase 2
22 Effect of Banaba (Lagerstroemia Speciosa) on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity Completed NCT02767869 Phase 2 Banaba;placebo
23 Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome Completed NCT02337933 Phase 2 Ursolic acid;Placebo
24 Mechanisms of Action of Probiotic and Protective Bacteria PCS 20, PCS 26, and LGG in Prevention of the Metabolic Syndrome Completed NCT02288572 Phase 2
25 A Randomised,Double-blind, Parallel Group, Placebo-controlled, Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of Oral GW677954 Capsules 2.5mg, 5mg, 10mg and 20mg a Day for 24 Weeks in Overweight Dyslipidaemic Subjects Completed NCT00264667 Phase 2 GW677954
26 Effect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion Completed NCT02114892 Phase 2 Resveratrol;Placebo
27 Metformin in the Diastolic Dysfunction of Metabolic Syndrome: MET-DIME Trial Completed NCT02017561 Phase 2 Metformin
28 The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study Completed NCT00400231 Phase 2 Study drugs: Metformin and fenofibrate;Study Drug: Metformin;Study Drug: fenofibrate;Metformin and Fenofibrate placebo
29 A Mechanistic Study of the Effects of LY518674 on HDL C Metabolism Completed NCT00327002 Phase 2 LY518674
30 Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome-AIM 2 Active, not recruiting NCT00455325 Phase 2 Placebo Comparator Limb 1;Chloroquine;Chloroquine;Chloroquine
31 Mechanisms of Cerebrovascular Control: Acute Insulin Surges Lead to Brain Hypoperfusion in Human Metabolic Syndrome Recruiting NCT02936687 Phase 1 NOS Inhibition;ET-1 Inhibition;NOS Inhibition Placebo;ET-1 Inhibition Placebo
32 An Investigation of the Effects of Consuming Oatcakes Containing 4g of Oat Beta-glucan on Physiological Parameters in Individuals at Risk of Developing Metabolic Syndrome Unknown status NCT02615444
33 Nutrition and Lifestyle Behaviours in Cardiometabolic Syndrome: Development of a Community-specific Peer-support Programme. Unknown status NCT03417128
34 The Metabolic Syndrome Among Childhood Acute Leukemia Survivors: Physiopathological Analysis Unknown status NCT02696304
35 Effect of Food Consumption on microRNA Related to Metabolic Syndrome. A Randomized Clinical Trial Unknown status NCT02606812
36 EFFECT OF Salvia Hispanica L. ( CHIA ) IN THE BIOCHEMICAL METABOLIC SYNDROME COMPONENTS IN PATIENTS IN THE NATIONAL MEDICAL CENTER WEST OF THE MEXICAN SOCIAL SECURITY INSTITUTE Unknown status NCT02480673
37 Functional Studies of High Density Lipoprotein in the Metabolic Syndrome Unknown status NCT00716300
38 Effect of a Low-Carbohydrate and High-Carbohydrate, High-Fiber Diet on Insulin Sensitivity and Risk Markers for Cardiovascular Disease in Men and Women With the Metabolic Syndrome Unknown status NCT00269646
39 Neural Mechanisms Predisposing to Cardiovascular Risk in Individuals With the Metabolic Syndrome: Benefits of Dietary Weight Loss, Weight Loss Maintenance and Aerobic Exercise Unknown status NCT00163943
40 Pilot Study: The Effects of Omega-3 Fatty Acids on Metabolic Syndrome and Vascular Structure in Metabolic Syndrome as Assessed by Carotid IMT Unknown status NCT00350194 Early Phase 1
41 Female Subfertility: a First Sign of Metabolic and Cardiovascular Anomalies? Unknown status NCT02136472
42 The Effects of High-intensity Aerobic Training in Patients With Metabolic Syndrome and Its Dose Response Study Unknown status NCT02130336
43 The Roles of Cytokines in the Mechanism of Insulin Resistance and Energy Balance Unknown status NCT00172614
44 A Population Based Cohort Study on Metabolic Syndrome Complications, and Mortality; (MetSCoM) Study Unknown status NCT02958579
45 Evaluation of Liver Fibrosis in HIV-infected Patients With Metabolic Syndrome Completed NCT02353767
46 The Effect of Pyridoxamine Supplementation on Vascular Function and Insulin Sensitivity; a Double-blind Randomized Placebo Controlled Trial in Abdominally Obese Subjects. Completed NCT02954588
47 Effects of Green-MED Diet Via the Gut-fat-brain Axis; DIRECT-PLUS Completed NCT03020186
48 OPUS(Optimal Well-being, Development and Health for Danish Children Through a Healthy New Nordic Diet) School Meal Study - - Cross Sectional Analyses From Baseline Investigations Completed NCT01577277
49 Environmental Triggers Of Cardiometabolic Disease Completed NCT01548300
50 Postprandial Effects of a Low vs. a High Glycemic Index Food Product on Metabolic Risk Markers in Lean and Obese Subjects Completed NCT00695825

Search NIH Clinical Center for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Genetic Tests for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Anatomical Context for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

MalaCards organs/tissues related to Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2:

40
Liver, Heart, Endothelial, Kidney, Bone, Skeletal Muscle, Small Intestine

Publications for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Articles related to Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2:

(show all 32)
# Title Authors PMID Year
1
Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. 57
11121050 2000
2
Gender Differences in the Relationship Between Financial Stress and Metabolic Abnormalities. 61
33630535 2021
3
Dietary Fiber and Its Source Are Associated with Cardiovascular Risk Factors in Korean Adults. 61
33419070 2021
4
Gender Differences in the Relationship Between Financial Stress and Metabolic Abnormalities. 61
33264260 2020
5
Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer. 61
32900627 2020
6
Correlation between vaspin and PANSS scores in schizophrenia patients with obesity. 61
32050814 2020
7
[Mutltifaceted biological roles of adiponectin]. 61
32540813 2020
8
Combined Effects of Alcohol and Metabolic Disorders in Patients With Chronic Liver Disease. 61
31255807 2020
9
Prevalence and Risk Factors of Hyperuricemia in Patients with Chronic Kidney Disease and Non-Alcoholic Fatty Liver. 61
32903892 2020
10
Eating Competence Is Associated with Lower Prevalence of Obesity and Better Insulin Sensitivity in Finnish Adults with Increased Risk for Type 2 Diabetes: The StopDia Study. 61
31905938 2019
11
The Burden of Atherosclerotic Cardiovascular Disease in South Asians Residing in Canada: A Reflection From the South Asian Heart Alliance. 61
32159121 2019
12
The relationship of abdominal girth with blood pressure, blood sugar and lipid profile among cardiac patients. 61
31435235 2017
13
A Systematic Review on Sasang Constitutional Type-Associated Susceptibility to Disorders in Korea. 61
27754711 2016
14
Bariatric Surgery: Pathophysiology and Outcomes. 61
27823611 2016
15
Predictive role of circulating endothelial-derived microparticles in cardiovascular diseases. 61
25697107 2015
16
Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. 61
25345753 2015
17
[Association between abdominal obesity and seminal oxidative damage in adults with metabolic syndrome]. 61
25327318 2014
18
Do statins increase the risk of diabetes or is it guilt by association? 61
24569555 2014
19
Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides. 61
23507055 2013
20
Associated factors of blood pressure control and complications of hypertension in hypertensive rural Thai populations of Baan Nayao, Chachoengsao Province. 61
22934445 2012
21
Association between obesity, high-sensitivity C-reactive protein ≥2 mg/L, and subclinical atherosclerosis: implications of JUPITER from the Multi-Ethnic Study of Atherosclerosis. 61
21474823 2011
22
Principal-component-based multivariate regression for genetic association studies of metabolic syndrome components. 61
21062472 2010
23
[Modulation of tissue exposure to cortisol, new perspective for reducing the metabolic risk associated with obesity]. 61
20411818 2010
24
[Is coronary artery disease different in women]. 61
20079601 2010
25
Abdominal obesity, metabolic syndrome in type 1 diabetic children and adolescents. 61
20455417 2009
26
Reducing the burden of coronary artery disease in India: challenges and opportunities. 61
19218731 2008
27
The link between abdominal obesity, metabolic syndrome and cardiovascular disease. 61
17110092 2007
28
Metabolic syndrome and gastrointestinal diseases. 61
17464454 2007
29
Prevalence of risk factors for cardiovascular disease in Brazilian renal transplant recipients. 61
17362755 2007
30
Association of hypertension with single nucleotide polymorphisms in the quantitative trait locus for abdominal obesity-metabolic syndrome on chromosome 17. 61
16511504 2006
31
Controversies in stable coronary artery disease. 61
16399156 2006
32
Association of essential hypertension with a microsatellite marker on chromosome 17. 61
15716982 2005

Variations for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Expression for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Search GEO for disease gene expression data for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2.

Pathways for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Pathways related to Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2 according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.2 SLC2A4 PPARG PPARD LEP INS IL6
2
Show member pathways
12.68 SLC2A4 SLC27A3 PPARG PPARD LEP ADIPOQ
3
Show member pathways
12.57 SLC2A4 LEP INS IL6 ADIPOQ
4 12.35 SLC2A4 PPARG INS ADIPOQ
5
Show member pathways
12.26 SLC2A4 PPARG LEP INS ADIPOQ
6
Show member pathways
12.09 SERPINE1 INS IL6 CRP
8 11.75 SERPINE1 INS IL6
9
Show member pathways
11.71 SLC2A4 SLC27A3 INS IL6
10
Show member pathways
11.69 SLC2A4 INS ADIPOQ
11 11.61 SLC2A4 PPARG LEP INS IL6 ADIPOQ
12 11.57 PPARG PPARD ADIPOQ
13 11.49 SLC2A4 LEP ADIPOQ
14 11.35 SLC2A4 SERPINE1 PPARG PPARD LEP INS
15 10.9 PPARG LEP ADIPOQ
16 10.7 SLC2A4 PPARG LEP IL6 ADIPOQ

GO Terms for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

Biological processes related to Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2 according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 9.97 SLC27A3 PPARG PPARD LEP AWAT1 ACSM1
2 carbohydrate metabolic process GO:0005975 9.9 SLC2A4 MAN2A2 INS BPGM
3 fatty acid metabolic process GO:0006631 9.87 SLC27A3 PPARG PPARD ACSM1
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.79 PPARD LEP INS
5 circadian rhythm GO:0007623 9.78 SERPINE1 LEP ADIPOQ
6 cellular response to insulin stimulus GO:0032869 9.78 SLC2A4 PPARG LEP ADIPOQ
7 response to nutrient GO:0007584 9.77 PPARG LEP ADIPOQ
8 positive regulation of interleukin-8 production GO:0032757 9.73 SERPINE1 IL6 ADIPOQ
9 fatty acid beta-oxidation GO:0006635 9.71 PPARD LEP ADIPOQ
10 placenta development GO:0001890 9.7 PPARG PPARD LEP
11 acute-phase response GO:0006953 9.69 INS IL6 CRP
12 glucose metabolic process GO:0006006 9.67 PPARD LEP INS ADIPOQ
13 fatty acid transport GO:0015908 9.63 SLC27A3 PPARD
14 regulation of fat cell differentiation GO:0045598 9.63 PPARG PPARD LEP
15 fatty acid catabolic process GO:0009062 9.62 PPARD LEP
16 negative regulation of smooth muscle cell migration GO:0014912 9.62 SERPINE1 PPARD
17 response to activity GO:0014823 9.62 PPARD LEP IL6 ADIPOQ
18 negative regulation of collagen biosynthetic process GO:0032966 9.61 PPARG PPARD IL6
19 negative regulation of cholesterol storage GO:0010887 9.58 PPARG PPARD
20 negative regulation of acute inflammatory response GO:0002674 9.58 PPARG INS
21 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.58 PPARG CRP ADIPOQ
22 positive regulation of fatty acid oxidation GO:0046321 9.55 PPARG PPARD
23 negative regulation of lipid storage GO:0010888 9.43 LEP IL6 CRP
24 positive regulation of fatty acid metabolic process GO:0045923 9.33 PPARG PPARD ADIPOQ
25 fatty acid oxidation GO:0019395 9.26 PPARG PPARD ADIPOQ ACSM1
26 glucose homeostasis GO:0042593 9.1 SLC2A4 PPARG LEP INS IL6 ADIPOQ

Sources for Abdominal Obesity-Metabolic Syndrome Quantitative Trait Locus 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....